Diana Ernst, RPh

The trial will continue as planned and final analysis is expected when the number of confirmed COVID-19 cases reaches 164.

In a statement, the Company noted that the actions being taken are considered “routine” when an unexplained illness is reported in a clinical trial.

Using a blood sample, the test is able to analyze more than 300 cancer-associated genes for alterations.

Vaccination with mRNA-1273, Moderna’s coronavirus disease 2019 (COVID-19) vaccine candidate, led to robust immune responses and protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in nonhuman primates.

Pfizer and BioNTech have selected a coronavirus disease 2019 (COVID-19) vaccine candidate and have initiated their phase 2/3 safety and efficacy trial.

The trial, which is the first to be implemented under Operation Warp Speed, is expected to enroll around 30,000 adults and will be conducted at multiple clinical research sites across the US.

The FDA has approved Zepzelca™ (lurbinectedin; Jazz Pharmaceuticals) for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.

The FDA has approved a new ready-to-dilute liquid formulation of Akynzeo® injection (fosnetupitant/palonosetron; Helsinn) for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, in combination with dexamethasone in adults.

The FDA has approved Cyramza (ramucirumab; Lilly) in combination with erlotinib, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.